Goldman Sachs tips Cochlear share price to rise 13%

One leading broker is bullish on Cochlear's shares…

| More on:
A man sees some good news on his phone and gives a little cheer.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Cochlear Limited (ASX: COH) share price could be heading higher from current levels.

That's the view of analysts at Goldman Sachs, which have just reiterated their buy rating on the hearing solutions company's shares.

This follows the release of a strong full year result for FY 2022 last week.

What is Goldman saying about the Cochlear share price?

According to note out of the investment bank, Goldman has reiterated its buy rating with an improved price target of $247.00.

Based on the current Cochlear share price of $218.86, this implies potential upside of 13% for investors over the next 12 months.

Goldman was impressed with the company's performance, noting that "in a highly challenging year Cochlear delivered +17% NPAT growth to reach the upper-half of the guided range."

The good news is that the broker is expecting more of the same in FY 2023. It said:

In our view, the backdrop for this year appears relatively more favourable, and we see clear scope for COH to deliver at the upper-end of another solid guidance (+8-13% to $290-305m, with further accretion possible from the Oticon Medical transaction, which is yet to close).

What about the medium term?

The good news for the Cochlear share price is that Goldman Sachs doesn't expect the company's growth to stop in FY 2023.

Its analysts believe the company is well-placed to continue this solid form through until at least FY 2025. It explained:

Overall, our NPAT forecast of $301m is at the upper-end of the guided range $290-305m, and we forecast a +10% CAGR from FY22-25E.

And while the broker acknowledges that Cochlear's shares are not cheap at current levels, it still believes they are good value compared to historic multiples and due to its positive and uncomplicated outlook. The broker said:

Whilst valuation of 28x EV/EBITDA appears high in absolute terms, it is still only in-line with its 5-year average and modestly above its 10-yr. Looking across the other 'recovery' plays in our coverage, there is less complexity to COH's near/mid-term earnings profile, and we believe it will ultimately experience lower and/or shorter-lived margin pressure through the pandemic period than peers.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Cochlear Ltd. The Motley Fool Australia has recommended Cochlear Ltd. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Broker Notes

person with large headphones looking puzzled holding their hand to their chin.
Broker Notes

Does Macquarie prefer Harvey Norman or JB Hi-Fi shares?

Both companies have market-beating long-term track records.

Read more »

A young man sits at his desk with a laptop and documents with a gas heater visible behind him as though he is considering the information in front of him. about the BHP share price
Broker Notes

Leading broker has just downgraded BHP shares. Is it time to sell?

Macquarie sees little upside. But why?

Read more »

A blockchain investor sits at his desk with a laptop computer open and a phone checking information from a booklet in a home office setting.
Broker Notes

Are non-bank lenders a lucrative alternative to the big 4 banks?

The big 4 banks are widely perceived as being fully valued or overvalued.

Read more »

A man in a business suit and tie places three wooden blocks with the numbers 1, 2, and 3 on them on top of each other.
Broker Notes

3 reasons to buy this booming ASX All Ords tech stock today

A leading broker forecasts more gains to come from this surging ASX All Ords tech stock.

Read more »

A man holding a cup of coffee puts his thumb up and smiles while at laptop.
Broker Notes

Why Bell Potter is bullish on this incredible ASX 200 share

This blue chip could be a strong long-term buy according to the broker.

Read more »

Broker analysing the share price.
Healthcare Shares

Expert: 2 ASX healthcare stocks to avoid before reporting season

Not all healthcare stocks are created equal.

Read more »

ASX shares Business man marking buy on board and underlining it
Broker Notes

Leading brokers name 3 ASX shares to buy today

Here's why brokers believe that now could be the time to snap up these shares.

Read more »

growth charts with small cap written on a sticky note
Small Cap Shares

Expert names 3 ASX small-cap stocks to buy in July

ASX small-cap stocks have greater ability to generate outsized returns, but can be difficult to discover.

Read more »